Cue Biopharma is trading 5.06% up in after-hours trading at $27.00, appearing to reflect continued post-earnings volatility and a rebound after two consecutive declining sessions.
- No new company-specific announcement was identified for August 18, 2026; major indexes fell that day.
- The August 14 earnings release reported $7.9 million revenue, a $153.1 million net loss, a $50 million private placement, and CUE-221 Phase 2 data expected by the end of the third quarter.